INTRODUCTION
A recent paper in the British Medical Journal suggested a 'no cure no pay' approach to drug usage and marketing. 1, 2 The argument behind this suggestion is that a large percentage of all prescribed drugs do not have the desired effect on patients' problems. The many influences on this poor outcome include wrong choice of drug, genetic factors, interactions, noncompliance and poor drug quality. 3 A 'no cure, no pay' approach can counter these problems by optimising the effect while still making the treatment economically feasible. If the drug does not cure, relieve, or prevent the patient's symptoms based on specific clinical measures or visible results, the public health service and the patient get their money back. A money-back guarantee might also be applicable if the patient suffers adverse effects. This is an unprecedented dimension of rational pharmacotherapy, and the approach has only been practiced eight times in the period from 1994 to 2005, worldwide. It has not yet been possible to evaluate the effect on price or on rational prescribing due to lack of evidence. One of the main arguments against the 'no cure, no pay' strategy is that it is too consumer oriented and suggests direct-to-consumer marketing. 4, 5 Although a 'no cure, no pay' set-up might sound appealing to the consumer-patient, what is the actual evidence? The objective of this paper is to investigate the attitudes and preferences toward a 'no cure, no pay' approach in the healthcare sector from a consumer-patient perspective.
METHODOLOGY
The data presented in this paper are based on three surveys:
Survey I: the patient/consumer perspective, generic This survey was conducted from 19th-27th April, 2005 on a representative sample of 3,001 Danes in the 18-70 year age group. The study was conducted through e-mail invitations to an html based questionnaire. The invitation to participate was sent to 6,100 persons, and the response rate equalled 49.8 per cent.
Survey II: the patient perspective, erectile dysfunction This survey was conducted from 15th-21st February, 2005 on a total of 613 men aged 40-70, and focused specifically on erectile dysfunction. The survey was conducted through e-mail and html-based questionnaire sent to a representative panel with Danish internet users with a filter for age and gender. The invitation to participate was sent to 1,000 persons and the response rate equalled 61.3 per cent.
Survey III: the patient perspective, erectile dysfunction This survey was conducted in June 2005 on a total of 1,081 men aged 40-70, and focused specifically on erectile dysfunction. The survey was conducted through e-mail and html-based questionnaire sent to a representative panel with Swedish internet users with a filter for age and gender. The invitation to participate was sent to 2,000 persons and the response rate equalled 54.1 per cent.
Validity of internet surveys
Web-based surveys introduce a new way of conducting surveys on consumers and patients in healthcare. Studies evaluating web-based survey-mode effects have generally shown them to more closely resemble self-administered mail surveys than interviewer-administered telephone surveys, although with lower item nonresponse. 6, 7 There are three preconditions for conducting representative online surveys: high internet penetration among the survey population; reliable sampling frame (eg an access panel); and valid sampling (and weighting) procedures. 8 For subjects such as healthcare in the USA, Bethell et al. 9 have documented that it is possible to obtain results using data collected on the internet similar to those using data collected from telephone-based survey methods. While the majority of Danes and Swedes (*85 per cent) have access to the web, some age and educational disparities remain. 10 The issue of internet penetration however, is not as complicated and problematic as reported in the USA. 11 With regard to sampling frame, the panel used in all three studies was constructed from telephone interviewing and considered representative of the Danish and Swedish populations. Finally, with regard to sampling and weighting procedures, the companies used Statistics Denmark and Statistics Sweden, independent, autonomous institutions that compile statistics on Danes and Swedes. Based on these considerations and the large number of respondents, the validity of the surveys is considered very acceptable. Another aspect of the present survey's preference for the online survey method over other methods is that erectile dysfunction is a highly sensitive topic not suited for telephone or personal interviews. An online survey allows the respondent to remain anonymous, which is expected to increase the validity of the individual response.
RESULTS
The data were analysed using SAS 9.1 and SAS Enterprise 3.0. Data were cleaned for missing responses. Data were weighted in terms of gender, age and geographical location, on the basis of an ideal distribution from Statistics Denmark, so that the results represent the respondent target group in the individual surveys, in relation to the population in general.
Survey I
The first survey, which had a generic focus on the conceptual understanding of 'no cure, no pay', found that 79 per cent of respondents had a positive or very positive attitude towards the idea that pharmaceutical companies have begun reimbursing the cost of medicine to insurers and patients if the medicine does not have the desired effect on the problem ( Figure 1 ). Significantly more men than women were 'very positive' about the initiative. The significant share of people with a 'very positive' response to the initiative increases with decreasing age, indicating that more young people than older people are very positive (Table 1) In response to the preference question about the extent to which the respondent would choose the medicine with the option of reimbursement if the medicine did not have the desired effect on the illness rather than another medicine without the option, the picture was slightly less positive than the attitude towards the idea generally. A total of 64 per cent would prefer the product with the reimbursement guarantee over the product without (Figure 2) . Gender was not significant in this context, but age still made a significant difference, with young people more inclined to choose the medicine with the option of reimbursement, a preference that falls with age. Geography and education do not appear to influence preference. As for the question regarding general attitude, people who are self-employed have a less positive approach to 'no cure, no pay' (53 per cent positive or very positive) than the other job categories, which are in the range of 59-72 per cent positive or very positive. Unlike for the question about attitude generally, income plays a role in the preference question, as people with low incomes are significantly more positive about the idea of buying the product with the reimbursement guarantee than people with higher incomes. Finally, significantly more people who characterise themselves as often ill show a 'very positive' attitude to the initiative; 55 per cent compared with 43-45 per cent for people with chronic illness, illness a couple times a year or people who are almost never ill. In contrast, how often they take medicine Some drug companies have begun reimbursing insurers and patients for the cost of medicine if it does not have the desired effect on the illness. What do you think of the idea? does not have any influence on preference.
Survey II
The second survey, with a specific focus on erectile dysfunction, found the following connections: in general, respondents (men, ages 40-70) will choose a medicinal product with the option of reimbursement if the product does not have the desired effect. This attitude increases with the degree of own payment (Figure 3 ). Respondents were asked about the severity of their erectile dysfunction: 'Of the last ten attempts, how many times did you find it difficult to get or maintain an erection?' There was no connection between the severity of the respondents' erectile dysfunction and their reported degree of willingness to buy medicine with the option of reimbursement; in other words, the severity of erectile dysfunction had no influence on their choice. People with erectile dysfunction, particularly those already in treatment and achieving good results however, are prepared to choose the medicinal product with the money-back guarantee rather than the product without that option (Figure 4 ). Age (40-70) has no bearing on the probability of whether a man will buy medicine with the option of reimbursement. Men who are married or cohabiting are more likely to buy medicine with the reimbursement option (15-17 per cent) than unmarried singles (9-10 per cent), although this is only valid in cases where the insurer is reimbursed, not when own payment is involved exclusively. With regard to urbanisation, there does not appear to be a difference in approach regardless of the population density of the respondents' residential area.
Survey III
The third survey, with a specific focus on erectile dysfunction in Sweden, found the following connections: in general, 84 per cent of respondents (men, ages 40-70) thought that an initiative offering reimbursement for a product that does not No fewer than 62.9 per cent of respondents believe that a reimbursement option would increase the credibility of the public health service, while 26.5 per cent of respondents do not believe it would influence their attitude. Correspondingly, 59.6 per cent find that a reimbursement option would increase the credibility of the product, while 29.6 per cent do not believe it would influence their attitude. A total of 42 per cent of respondents would be more likely to choose a product with the option of reimbursement if it does not have the desired effect over a corresponding product without that option. A total of 53 per cent would not be influenced by the option. The same is true in the specific case of products for treating erectile dysfunction: here, 43.5 per cent of respondents would be more likely to choose a product with the option of reimbursement if the product does not have the desired effect over a corresponding product without this option. A total of 46 per cent would not be swayed by the option.
DISCUSSION
All three surveys show a positive approach to the 'no cure, no pay' concept seen in a consumer-patient perspective. The first and third surveys document positive acceptance of the concept by 79 per cent and 84 per cent of respondents, respectively. Surveys II and III document that 52 per cent and 43 per cent of respondents, respectively, will be more likely to choose an erectile dysfunction product with the reimbursement option if the product does not have the desired effect over a corresponding product without that option. Surveys I and II also show that people diagnosed as chronically ill have the same attitude to the question as healthy people. This however, only shows that people with chronic illnesses are loyal to the efficacious products they already use, and thus a 'no cure, no pay' initiative is not meaningful to this category of patient. People who are often ill, but do not have a chronic illness, however, are significantly more positive than all other groups. The rationale here is that people who are often ill are exposed to various types of medication every time, and thus the reimbursement option makes sense to this group. Drug consumption does not Seen from a commercial point of view, it is evident that a 'no cure, no pay' approach to a treatment area is an interesting business proposition. Patientscustomers generally accept this form of marketing and have few reservations. It is interesting that this type of initiative is, in fact, a very strong driver with respect to the intent to choose one product rather than another.
CONCLUSION
This survey documents that 'no cure, no pay' drug initiatives are accepted by patients and customers in Denmark and Sweden. At the same time, 'no cure, no pay' initiatives appear to be a strong business strategy for influencing the buying intentions of patients and customers. Results like these will motivate most marketing directors to focus more on these types of initiatives. Here it is important to point out that 'no cure, no pay' initiatives should not be designed as purely marketing strategies. Product candidates for a 'no cure, no pay' strategy must be effective, preferably for a large proportion of patients. Obviously, a 'no cure, no pay' policy for drugs with poor documentation and little effect will not influence rational pharmacotherapy. Rather, in such cases, the initiative would be considered aggressive or frivolous marketing. If good documentation is available on a drug and one drug is either better than or as good as the drug of first choice, however, a 'no cure, no pay' strategy could be used to support a message about product benefits. Here the compliance initiatives introduced as part of the 'no cure, no pay' strategies will influence decisions about rational pharmacotherapy. The greatest obstacle to expanding the concept is the possibility of its misuse as cheap marketing: hence the reservations of healthcare staff and politicians about the concept. Misuse as cheap marketing would be no help to the industry in general in its attempt to lessen tension between the pharmaceutical industry and health authorities over drug marketing.
